Literature DB >> 7932824

Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.

D E Goldgar1, D F Easton, L A Cannon-Albright, M H Skolnick.   

Abstract

BACKGROUND: Cancer has long been recognized to have a familial component. Elevated risks for cancers at the same site for relatives of cancer probands have been reported for both common cancers and a number of the rarer cancer sites. For a particular cancer site, however, the estimated risks to relatives have varied considerably depending on criteria for selection of probands, how cancers were determined in relatives, and overall study design. Not surprisingly, the estimated risks of other cancers in relatives of probands with cancer at a given site have been subject to even more variation.
PURPOSE: The aim of this study was to use the Utah Population Database resource to systematically study familial clustering of 28 distinct cancer site definitions among first-degree relatives (parents, siblings, and off-spring) of cancer probands.
METHODS: We estimated familial relative risks from the Utah Population Database by identifying all cases of cancer in these first-degree relatives. These observed values were compared with those expected based on cohort-specific internal rates calculated from 399,786 relatives of all individuals in the Utah Population Database known to have died in Utah.
RESULTS: All sites showed an excess of cancers of the same site among relatives, with thyroid and colon cancers and lymphocytic leukemia showing the highest familial risks. When the analyses were restricted to cases with early ages at diagnosis, increased familial components for most cancer sites became evident. A significant difference in familial relative risk (FRR) between male (FRR = 4.04; 95% confidence interval [CI] = 3.13-5.07) and female (FRR = 2.24; 95% CI = 1.54-3.08) probands was found for colon cancer. Highly significant familial associations (one-sided; P < .001) were found among breast, colon, and prostate cancers and between breast and thyroid cancers. Statistically significant (one-sided, P < .01) associations were also found between tobacco-associated sites (lung, larynx, lip, and cervix).
CONCLUSIONS: This study represents a unique comprehensive population-based study of familial cancer. The familial associations reported here will be useful in generating hypotheses about specific genetic and environmental factors that can be tested in genetic linkage and case-control studies.

Entities:  

Mesh:

Year:  1994        PMID: 7932824     DOI: 10.1093/jnci/86.21.1600

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  288 in total

1.  Highly skewed X-chromosome inactivation is associated with idiopathic recurrent spontaneous abortion.

Authors:  M C Lanasa; W A Hogge; C Kubik; J Blancato; E P Hoffman
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

2.  Segregation analyses of 1,476 population-based Australian families affected by prostate cancer.

Authors:  J Cui; M P Staples; J L Hopper; D R English; M R McCredie; G G Giles
Journal:  Am J Hum Genet       Date:  2001-04-11       Impact factor: 11.025

3.  Evidence for a prostate cancer-susceptibility locus on chromosome 20.

Authors:  R Berry; J J Schroeder; A J French; S K McDonnell; B J Peterson; J M Cunningham; S N Thibodeau; D J Schaid
Journal:  Am J Hum Genet       Date:  2000-05-16       Impact factor: 11.025

4.  Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer.

Authors:  R Berry; D J Schaid; J R Smith; A J French; J J Schroeder; S K McDonnell; B J Peterson; Z Y Wang; J D Carpten; S G Roberts; D J Tester; M L Blute; J M Trent; S N Thibodeau
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

5.  Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21.

Authors:  J D McKay; F Lesueur; L Jonard; A Pastore; J Williamson; L Hoffman; J Burgess; A Duffield; M Papotti; M Stark; H Sobol; B Maes; A Murat; H Kääriäinen; M Bertholon-Grégoire; M Zini; M A Rossing; M E Toubert; F Bonichon; M Cavarec; A M Bernard; A Boneu; F Leprat; O Haas; C Lasset; M Schlumberger; F Canzian; D E Goldgar; G Romeo
Journal:  Am J Hum Genet       Date:  2001-07-02       Impact factor: 11.025

6.  A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity.

Authors:  C L Hsieh; I Oakley-Girvan; R R Balise; J Halpern; R P Gallagher; A H Wu; L N Kolonel; L E O'Brien; I G Lin; D J Van Den Berg; C Z Teh; D W West; A S Whittemore
Journal:  Am J Hum Genet       Date:  2001-06-12       Impact factor: 11.025

7.  Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation.

Authors:  Lindsay B Robertson; Georgina N Armstrong; Bianca D Olver; Amy L Lloyd; Sanjay Shete; Ching Lau; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Ping Yang; Amanda Lynn Rynearson; Amanda L Rynerason; Margaret Wrensch; Lucie McCoy; John K Wienkce; Bridget McCarthy; Faith Davis; Nicholas A Vick; Christoffer Johansen; Hanne Bødtcher; Siegal Sadetzki; Revital Bar-Sade Bruchim; Galit Hirsh Yechezkel; Ulrika Andersson; Beatrice S Melin; Melissa L Bondy; Richard S Houlston
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

8.  The effect of disease penetrance, family size, and age of onset on family history with application to setting eligibility criteria for genetic testing.

Authors:  Alexandre Sibert; David E Goldgar
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

9.  Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.

Authors:  J D McKay; D Thompson; F Lesueur; K Stankov; A Pastore; C Watfah; S Strolz; G Riccabona; R Moncayo; G Romeo; D E Goldgar
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

10.  Discovery of common variants associated with low TSH levels and thyroid cancer risk.

Authors:  Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Jon G Jonasson; Gisli Masson; Huiling He; Aslaug Jonasdottir; Asgeir Sigurdsson; Simon N Stacey; Hrefna Johannsdottir; Hafdis Th Helgadottir; Wei Li; Rebecca Nagy; Matthew D Ringel; Richard T Kloos; Marieke C H de Visser; Theo S Plantinga; Martin den Heijer; Esperanza Aguillo; Angeles Panadero; Enrique Prats; Almudena Garcia-Castaño; Ana De Juan; Fernando Rivera; G Bragi Walters; Hjordis Bjarnason; Laufey Tryggvadottir; Gudmundur I Eyjolfsson; Unnur S Bjornsdottir; Hilma Holm; Isleifur Olafsson; Kristleifur Kristjansson; Hoskuldur Kristvinsson; Olafur T Magnusson; Gudmar Thorleifsson; Jeffrey R Gulcher; Augustine Kong; Lambertus A L M Kiemeney; Thorvaldur Jonsson; Hannes Hjartarson; Jose I Mayordomo; Romana T Netea-Maier; Albert de la Chapelle; Jon Hrafnkelsson; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2012-01-22       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.